No Data Yet
Vaso Corporation announced on December 17, 2025, the fifth extension of its sales representation agreement with GE HealthCare, continuing the partnership through December 31, 2030.
GE HealthCare has partnered with Indonesia's Ministry of Health to supply over 300 advanced CT scanners, part of the country's largest-ever healthcare infrastructure investment.
GE HealthCare's fair value estimate rose to $89.22, drawing mixed analyst revisions as BTIG cut its price target to $87 while Morgan Stanley raised its to $80.
Stryker (SYK), Tempus AI (TEM), and GE HealthCare (GEHC) are identified as key beneficiaries of AI integration in MedTech, a sector that saw 209 AI-enabled medical devices receive FDA approval in 2025.
GE HealthCare (GEHC) has been identified as a strong value stock based on its favorable valuation metrics, according to analysis from Zacks Investment Research. This designation comes as investors navigate a mixed market with pressure on high-growth technology stocks.
An analysis of key S&P 500 stocks, including Constellation Brands (STZ), Intuitive Surgical (ISRG), and Quest Diagnostics (DGX), reveals significant performance divergence. While some consumer-facing companies show signs of revenue strain, healthcare technology firms are demonstrating robust, data-driven growth, reflecting broader economic and technological shifts.
Hologic reported a 1.5% rise in diagnostics revenue, propelled by strong U.S. sales. The company also secured expanded CE marking in the EU for its Genius Digital Diagnostics System, broadening its application to both cell and tissue specimens.
Healthcare technology and services stocks are exhibiting significant bullish momentum, driven by accelerating enterprise spending on digital transformation and artificial intelligence. A recent PitchBook analyst note identifies a $155 billion addressable market for healthcare AI agents, validating investor interest and signaling a new phase of sector growth focused on efficiency and automation.